Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Roivant Sciences Ltd (ROIV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: ROIV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $16.75
Year Target Price $16.75
| 6 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.91% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.74B USD | Price to earnings Ratio - | 1Y Target Price 16.75 |
Price to earnings Ratio - | 1Y Target Price 16.75 | ||
Volume (30-day avg) - | Beta 1.16 | 52 Weeks Range 8.73 - 13.05 | Updated Date 06/29/2025 |
52 Weeks Range 8.73 - 13.05 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4823.84% |
Management Effectiveness
Return on Assets (TTM) -10.73% | Return on Equity (TTM) -12.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2956270137 | Price to Sales(TTM) 266.51 |
Enterprise Value 2956270137 | Price to Sales(TTM) 266.51 | ||
Enterprise Value to Revenue 101.75 | Enterprise Value to EBITDA 0.74 | Shares Outstanding 679806016 | Shares Floating 341113090 |
Shares Outstanding 679806016 | Shares Floating 341113090 | ||
Percent Insiders 30.68 | Percent Institutions 83.5 |
Analyst Ratings
Rating 4.5 | Target Price 16.75 | Buy 3 | Strong Buy 6 |
Buy 3 | Strong Buy 6 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Roivant Sciences Ltd
Company Overview
History and Background
Roivant Sciences Ltd. was founded in 2014 by Vivek Ramaswamy. It focuses on acquiring and developing promising drug candidates from other pharmaceutical companies, aiming to accelerate their development and commercialization through a diversified portfolio of 'Vants'.
Core Business Areas
- Drug Development: Roivant identifies and acquires promising drug candidates from other pharmaceutical companies, de-risking their portfolio. Then they develop the drugs via specialized Vants.
- Vant Creation and Management: Roivant creates and manages multiple subsidiary companies ('Vants'), each focused on a specific therapeutic area or drug candidate. Each of these 'Vants' are independently run.
Leadership and Structure
Matt Gline is the CEO of Roivant Sciences. The company operates under a decentralized 'Vant' structure, with each Vant having its own management team. The company is publicly traded.
Top Products and Market Share
Key Offerings
- VTAMA (tapinarof): A topical non-steroidal cream for the treatment of plaque psoriasis in adults. Developed by Dermavant Sciences, a Roivant company. Market share data is not readily available, but it competes with other topical treatments like corticosteroids and vitamin D analogs (e.g., calcipotriene). Competitors include LEO Pharma (Enstilar), Bausch Health (Duobrii), and other generics. Peak sales could reach $1 billion.
- RVT-3101 (TL1A antibody): An anti-TL1A antibody being developed for the treatment of inflammatory bowel disease (IBD). It is in Phase 3 trials. Competitors include Takeda (Entyvio), AbbVie (Skyrizi, Rinvoq), and other emerging TL1A inhibitors. Market share is prospective.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Trends include personalized medicine, biologics, and digital health integration.
Positioning
Roivant Sciences operates as a de-risked biotech firm, acquiring and developing promising assets. They focus on operational efficiency and strategic partnerships. Their Vant structure is unique.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be over $1 trillion. Roivant focuses on specific therapeutic areas with significant unmet needs. Its TAM is dependent on the success of its current pipeline drugs.
Upturn SWOT Analysis
Strengths
- Innovative business model
- Diversified pipeline
- Experienced management team
- Strategic partnerships
Weaknesses
- Reliance on external acquisitions
- High R&D expenses
- Regulatory risks
- Dependence on Vant performance
Opportunities
- Expanding pipeline through acquisitions
- Entering new therapeutic areas
- Strategic collaborations with larger pharmaceutical companies
- Leveraging data and technology
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from larger pharmaceutical companies
- Patent expirations
Competitors and Market Share
Key Competitors
- ABBV
- PFE
- MRK
- BMY
- LLY
Competitive Landscape
Roivant possesses a unique business model leveraging Vants. While it is nimble, it faces competition from pharmaceutical giants (ABBV, PFE, MRK, BMY, LLY) with greater resources and established market presence.
Major Acquisitions
Silicon Therapeutics
- Year: 2021
- Acquisition Price (USD millions): 450
- Strategic Rationale: Acquisition of Silicon Therapeutics was to bolster Roivant's drug discovery platform using physics-based computational methods.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by acquisitions of drug candidates and the formation of new Vants.
Future Projections: Future growth depends on the success of the pipeline, regulatory approvals, and market adoption. Analyst estimates vary depending on these factors.
Recent Initiatives: Recent initiatives include advancing key drug candidates through clinical trials and pursuing strategic collaborations.
Summary
Roivant Sciences has a unique approach to drug development, acquiring and developing promising drug candidates. They have a diversified pipeline and strategic partnerships. They face risks associated with R&D, regulatory approval, and competition. The company's success relies on efficient Vant management and pipeline execution.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Roivant Sciences' official website
- SEC filings (10-K, 10-Q)
- Analyst reports
- Company press releases
- Third-party financial websites
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data and analyst estimates are subject to change. Past performance is not indicative of future results. Roivant is a dynamic company. Specific financials need to be pulled live to ensure accuracy.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Roivant Sciences Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-10-01 | CEO & Director Mr. Matthew Gline | ||
Sector Healthcare | Industry Biotechnology | Full time employees 750 | Website https://roivant.com |
Full time employees 750 | Website https://roivant.com | ||
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.